Plus Therapeutics Reports Q2 2019 Financial and Business Results

    NEXT STORY
    FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
    PREV STORY
    Delcath Systems Announces $9.5 Million Private Placement
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cerner and i2i Population Health Collaborate to Better Serve Medicaid Population

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease

    Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected ...

    author_avatar
    NASDAQ Market News

    Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit

    PRINCETON, N.J., April 04, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage ...

    author_avatar
    NASDAQ Market News